Physician profile
Kevin Patrick Oreilly
NPI 1174531354
$3,252.31
in general payments reported to CMS, 2019-2025
17 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $13.45 · 2021: $223 · 2022: $911 · 2023: $558 · 2024: $567 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404 · Education: $75.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.11 |
| Education | $75.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $609.21 | 2019-2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $555.73 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $397.11 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $365.83 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $245.14 | 2023-2024 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $170.24 | 2023-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $152.17 | 2022-2023 | |
| Amgen INC. | $142.83 | 2025 | Tavneos, Krystexxa |
| Novo Nordisk INC | $121.84 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $106.33 | 2022 | |
| Pharmacosmos Therapeutics INC. | $101.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $89.72 | 2019 | |
| Medtronic, INC. | $89.01 | 2024 | Symplicity G3 |
| Travere Therapeutics, INC. | $63.12 | 2023-2025 | Filspari |
| Horizon Therapeutics Plc | $14.96 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $14.34 | 2025 | |
| Strongbridge US INC. | $13.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Oreilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.